Androstanedione

Identification

Generic Name
Androstanedione
DrugBank Accession Number
DB01561
Background

Not Available

Type
Small Molecule
Groups
Experimental, Illicit
Structure
Weight
Average: 288.4244
Monoisotopic: 288.20893014
Chemical Formula
C19H28O2
Synonyms
  • 5alpha-Androstan-3,17-dione
  • 5α-androstane-3,17-dione
External IDs
  • NSC-60796
  • NSC-9897

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
A17-beta-hydroxysteroid dehydrogenase type 1
inhibitor
Humans
USteroid Delta-isomeraseNot AvailableComamonas testosteroni
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
PathwayCategory
Androstenedione MetabolismMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as androgens and derivatives. These are 3-hydroxylated C19 steroid hormones. They are known to favor the development of masculine characteristics. They also show profound effects on scalp and body hair in humans.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Steroids and steroid derivatives
Sub Class
Androstane steroids
Direct Parent
Androgens and derivatives
Alternative Parents
3-oxo-5-alpha-steroids / 17-oxosteroids / Cyclic ketones / Organic oxides / Hydrocarbon derivatives
Substituents
17-oxosteroid / 3-oxo-5-alpha-steroid / 3-oxosteroid / Aliphatic homopolycyclic compound / Androgen-skeleton / Carbonyl group / Cyclic ketone / Hydrocarbon derivative / Ketone / Organic oxide
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
androstane-3,17-dione (CHEBI:15994) / C19 steroids (androgens) and derivatives (LMST02020085)
Affected organisms
Not Available

Chemical Identifiers

UNII
2KR72RNR8Z
CAS number
846-46-8
InChI Key
RAJWOBJTTGJROA-WZNAKSSCSA-N
InChI
InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h12,14-16H,3-11H2,1-2H3/t12-,14-,15-,16-,18-,19-/m0/s1
IUPAC Name
(3aS,3bR,5aS,9aS,9bS,11aS)-9a,11a-dimethyl-hexadecahydro-1H-cyclopenta[a]phenanthrene-1,7-dione
SMILES
[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])CC(=O)CC[C@]12C

References

Synthesis Reference

Fabrizio Orzi, Antonio Longo, Matteo D'Anello, Natale Barbugian, "Process for the preparation of 4-amino-unsaturated androstanedione derivatives." U.S. Patent US5241090, issued September, 1989.

US5241090
General References
Not Available
Human Metabolome Database
HMDB0000899
KEGG Compound
C00674
PubChem Compound
222865
PubChem Substance
46508701
ChemSpider
193520
BindingDB
50025405
ChEBI
15994
ChEMBL
CHEMBL1230438
ZINC
ZINC000003881403
PDBe Ligand
5SD
Wikipedia
Androstanedione
PDB Entries
1ohs / 1qyw / 4xo6

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00739 mg/mLALOGPS
logP3.4ALOGPS
logP3.97Chemaxon
logS-4.6ALOGPS
pKa (Strongest Basic)-7.1Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count2Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area34.14 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity82.78 m3·mol-1Chemaxon
Polarizability33.83 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleYesChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9892
Caco-2 permeable+0.8115
P-glycoprotein substrateNon-substrate0.535
P-glycoprotein inhibitor IInhibitor0.7024
P-glycoprotein inhibitor IINon-inhibitor0.6687
Renal organic cation transporterNon-inhibitor0.7299
CYP450 2C9 substrateNon-substrate0.8178
CYP450 2D6 substrateNon-substrate0.8995
CYP450 3A4 substrateSubstrate0.6705
CYP450 1A2 substrateNon-inhibitor0.8895
CYP450 2C9 inhibitorNon-inhibitor0.9285
CYP450 2D6 inhibitorNon-inhibitor0.9635
CYP450 2C19 inhibitorNon-inhibitor0.9403
CYP450 3A4 inhibitorNon-inhibitor0.8781
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9568
Ames testNon AMES toxic0.9358
CarcinogenicityNon-carcinogens0.8986
BiodegradationNot ready biodegradable0.9685
Rat acute toxicity1.8398 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8695
hERG inhibition (predictor II)Non-inhibitor0.6339
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (12.1 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-MSGC-MSsplash10-003u-9711000000-845e34a01c44999f2ded
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-03ea-0490000000-e4819053bc47c4809a6c
GC-MS Spectrum - EI-BGC-MSsplash10-000i-2790000000-3265da77fd4cc7bfa1c9
GC-MS Spectrum - GC-MSGC-MSsplash10-003u-9711000000-845e34a01c44999f2ded
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-000i-0090000000-decf354145d0bc46e624
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-01vk-4910000000-1f05b00fe5f61dd134c3
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-05ng-9800000000-ef0555e1d54150aaffd2
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0aou-0290000000-ffd1b454b311f471cb73
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-014i-0390000000-f4995b2047bec58846f5
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-00di-0390000000-a4cf943964aae2cffee6
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00dr-0090000000-533e92992b5287f7efa4
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-712e47bf411f8983ac88
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0fk9-2590000000-103d1711db93d1d67f0d
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-f4ed9d4a226a312b6dc2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-007a-1090000000-df491fa345beb3a2de43
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-004i-2900000000-df2158133dc6a472703e
1H NMR Spectrum1D NMRNot Applicable
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-176.5290819
predicted
DarkChem Lite v0.1.0
[M-H]-176.4997819
predicted
DarkChem Lite v0.1.0
[M-H]-176.5322819
predicted
DarkChem Lite v0.1.0
[M-H]-176.5617819
predicted
DarkChem Lite v0.1.0
[M-H]-172.22343
predicted
DeepCCS 1.0 (2019)
[M+H]+176.8174819
predicted
DarkChem Lite v0.1.0
[M+H]+176.6704819
predicted
DarkChem Lite v0.1.0
[M+H]+176.8882819
predicted
DarkChem Lite v0.1.0
[M+H]+176.8478819
predicted
DarkChem Lite v0.1.0
[M+H]+174.2559
predicted
DeepCCS 1.0 (2019)
[M+Na]+177.0201819
predicted
DarkChem Lite v0.1.0
[M+Na]+176.7613819
predicted
DarkChem Lite v0.1.0
[M+Na]+177.0692819
predicted
DarkChem Lite v0.1.0
[M+Na]+177.2858819
predicted
DarkChem Lite v0.1.0
[M+Na]+180.5187
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
General Function
Favors the reduction of estrogens and androgens. Converts estrone (E1) to a more potent estrogen, 17beta-estradiol (E2) (PubMed:8994190). Also has 20-alpha-HSD activity. Uses preferentially NADH
Specific Function
17-beta-hydroxysteroid dehydrogenase (NADP+) activity
Gene Name
HSD17B1
Uniprot ID
P14061
Uniprot Name
17-beta-hydroxysteroid dehydrogenase type 1
Molecular Weight
34949.715 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
  4. Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Kind
Protein
Organism
Comamonas testosteroni
Pharmacological action
Unknown
General Function
Not Available
Specific Function
steroid delta-isomerase activity
Gene Name
ksi
Uniprot ID
P00947
Uniprot Name
Steroid Delta-isomerase
Molecular Weight
13398.04 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Cytosolic aldo-keto reductase that catalyzes the NADH and NADPH-dependent reduction of ketosteroids to hydroxysteroids. Acts as a NAD(P)(H)-dependent 3-, 17- and 20-ketosteroid reductase on the steroid nucleus and side chain and regulates the metabolism of androgens, estrogens and progesterone (PubMed:10622721, PubMed:11165022, PubMed:7650035, PubMed:9415401, PubMed:9927279). Displays the ability to catalyze both oxidation and reduction in vitro, but most probably acts as a reductase in vivo since the oxidase activity measured in vitro is inhibited by physiological concentration of NADPH (PubMed:11165022, PubMed:14672942). Acts preferentially as a 17-ketosteroid reductase and has the highest catalytic efficiency of the AKR1C enzyme for the reduction of delta4-androstenedione to form testosterone (PubMed:20036328). Reduces prostaglandin (PG) D2 to 11beta-prostaglandin F2, progesterone to 20alpha-hydroxyprogesterone and estrone to 17beta-estradiol (PubMed:10622721, PubMed:10998348, PubMed:11165022, PubMed:15047184, PubMed:19010934, PubMed:20036328). Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha-androstan-3-alpha,17-beta-diol (3-alpha-diol) (PubMed:10557352, PubMed:10998348, PubMed:11165022, PubMed:14672942, PubMed:7650035, PubMed:9415401). Also displays retinaldehyde reductase activity toward 9-cis-retinal (PubMed:21851338)
Specific Function
15-hydroxyprostaglandin-D dehydrogenase (NADP+) activity
Gene Name
AKR1C3
Uniprot ID
P42330
Uniprot Name
Aldo-keto reductase family 1 member C3
Molecular Weight
36852.89 Da
References
  1. Adeniji A, Uddin MJ, Zang T, Tamae D, Wangtrakuldee P, Marnett LJ, Penning TM: Discovery of (R)-2-(6-Methoxynaphthalen-2-yl)butanoic Acid as a Potent and Selective Aldo-keto Reductase 1C3 Inhibitor. J Med Chem. 2016 Aug 25;59(16):7431-44. doi: 10.1021/acs.jmedchem.6b00160. Epub 2016 Aug 12. [Article]

Drug created at July 31, 2007 13:10 / Updated at August 26, 2024 19:22